<?xml version='1.0' encoding='UTF-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN" "JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
  <front>
    <journal-meta id="journal-meta-e7d1fcc7050146358e462dac0435a28a">
      <journal-id journal-id-type="nlm-ta">Sciresol</journal-id>
      <journal-id journal-id-type="publisher-id">Sciresol</journal-id>
      <journal-id journal-id-type="journal_submission_guidelines">https://ijpccr.com/#</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Preclinical &amp; Clinical Research</journal-title>
      </journal-title-group>
      <issn publication-format="electronic">XXXX-XXXX</issn>
      <issn publication-format="print"/>
    </journal-meta>
    <article-meta id="article-meta-85df3832177a41448aaafe60fbfd4fd1">
      <article-id pub-id-type="doi">10.51131/IJPCCR/v2i1.8</article-id>
      <title-group>
        <article-title id="article-title-bbe617e331fd40698f8312748ca31f3c">Smoldering Vogt-Koyanagi-Harada disease with extra ocular involvement — A case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid"/>
          <name id="n-676b8f977ddc">
            <surname>Savitha</surname>
            <given-names>D P</given-names>
          </name>
          <xref id="x-4fcbadce0404" rid="a-3e33798a009e" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name id="n-b1b881bb7043">
            <surname>Padmajothi</surname>
            <given-names>M S</given-names>
          </name>
          <email>doctorpadmajothi@yahoo.co.in</email>
          <xref id="x-13eb8ef8a8a6" rid="a-86e39948fdb7" ref-type="aff">2</xref>
        </contrib>
        <aff id="a-3e33798a009e">
          <institution>Assistant professor, Department of ophthalmology, Basaveshwara Medical College and Hospital</institution>
          <addr-line>Chitradurga, Karnataka, 577502</addr-line>
          <country country="IN">India</country>
        </aff>
        <aff id="a-86e39948fdb7">
          <institution>Professor and HOD, Department of ophthalmology, Basaveshwara Medical College and Hospital</institution>
          <addr-line>Chitradurga, Karnataka, 577502</addr-line>
          <country country="IN">India</country>
        </aff>
      </contrib-group>
      <volume>2</volume>
      <issue>1</issue>
      <permissions>
        <copyright-year>2021</copyright-year>
      </permissions>
      <abstract id="abstract-abstract-title-211cf4e166db4adfa29a13b75371f344">
        <title id="abstract-title-211cf4e166db4adfa29a13b75371f344">Abstract</title>
        <p id="paragraph-85d07df3d3b64481b25b5206ebb742cb">To report a case of smoldering vogt-koyanagi-harada disease with extra-ocular involvement. A 45-years-old male presented with diminished vision in BE for one 1 — week associated with redness, pain, watering, intolerance to light with tinnitus also gives a history of similar complaints, in the past 2years. Examination revealed both eye visual acuity CF1/2 meters. Slit-lamp examination showed conjunctival ingestion, mutton fat KP’s, sluggishly reactive pupil with multiple broken posterior synechaie. Fundus showed grade 2 vitreous cells with multiple opacities, diffuse retinochoroidal thickening with disc edema. Tonometry was 16 and 29 mmhg respectively. B-scan showed multiple vitreous echo’s, diffuse retino-choroidal complex thickening with multiple shallow serous retinal detachment. After routine investigations patient was started on topical and systemic steroids. Lumbar puncture showed 82% lymphocytic pleocytosis. The patient recovered well with 6/24 vision in BE with a resolution of fundus finding at 6week followup. High index of suspicion, timely diagnosis and management are crucial to prevent vision threatening complications in VKH disease.</p>
      </abstract>
      <kwd-group id="kwd-group-ab7822d2a06449b3847bb3828995a195">
        <title>Keywords</title>
        <kwd>Vogt­koyanagi­harada disease</kwd>
        <kwd>retinochoroidal thickening</kwd>
        <kwd>serous retinal detachment</kwd>
        <kwd>tinnitus</kwd>
        <kwd>CSF pleocytosis</kwd>
        <kwd>systemic steroids</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement>None</funding-statement>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title id="title-0745372e7b3b4bcba27739d2be9aba99">Introduction</title>
      <p id="paragraph-1dc5e63120c04756bd25b95e227dfb08">The uveomeningeal syndromes are a heterogeneous group of disorders or conditions that share a common characteristic, the affection of the retina, uvea and meninges, <xref id="xref-516a0102ed4f4d29aa3ead4e5c44b0e2" rid="R104280321731170" ref-type="bibr">1</xref> their causes can be infectious, due to neoplastic process or to systemic diseases. This is a systemic autoimmune disease characterized mainly by a bilateral granulomatous panuveitis, in which antibodies are produced against tissues rich in melanocytes such as the retina, the inner ear, the meninges, skin and hair, <xref id="xref-f4603f1214b4499b93694510f7d320ed" rid="R104280321731168" ref-type="bibr">2</xref> which explains its extraocular manifestations and its clinical presentation. Occurs more commonly in darkly pigmented races. Onset is usually in the 2<sup id="superscript-c3d9ffbc3c874d0582917d1d0e7d0648">nd</sup> to 5<sup id="superscript-5f81c211d9bf4a9a91eff5e1602f07a3">th</sup> decade of life VKH disease has 4 clinical phases of presentation consisting of the following. <sup id="s-67e41f56f7ab"><xref id="x-47df8baf8fc2" rid="R104280321731166" ref-type="bibr">3</xref></sup></p>
      <p id="p-e6e27d4fb32d"><bold id="strong-17ff7ebe755c4e8fb772e363c2c6e1fe">Prodromal phase —</bold> Nonspecific symptoms among which are fever, headache, nausea, meningism, vertigo and disacusia, rarely include ataxia, confusion and neurological focality. It usually lasts 3 to 5 days.﻿﻿<bold id="strong-2ae737477b384ab9afb0b4e8a793d885">Acute </bold><bold id="strong-e829cee7eb324a11ae96118568934764">uveitic phase</bold> — Decreased visual acuity, usually unilateral onset, then contralateral with a difference of 1-3 days, photophobia, iridocyclitis, retrokeratic deposits, ocular hypertension, vitreitis. Choroiditis that results in rupture of the external hematorretinal barrier (pigmented epithelium of the retina), causing exudative retinal detachments. It can cause acute glaucoma. It lasts several weeks.<bold id="strong-1ec9201125e14a5bb5aae21027ab2725">Convalescence phase —</bold> Retinal detachments gradually subside and uveitis begins to subside. There is a pigmentary redistribution that gives rise to an eye fund "like sunset" (sunset glow fundus). It can last for months.<bold id="strong-756224bf00e04716994326377a2c9c13">Chronic recurrent phase</bold> — It can interrupt the convalescent phase with recurrent anterior uveitis. There is the formation of synechiae, pupillary block, iris atrophy, cataracts and glaucoma.</p>
    </sec>
    <sec>
      <title id="t-f2d97b235052">Systemic manifestations </title>
      <p id="paragraph-440ed4a652d448cd8fed741e4a7b7379"><bold id="strong-0b2ed5535bca410bb522cfd414cc728c">Neurological symptoms</bold>: Headache, meningism, encephalitis, paralysis of the cranial nerves, aphasia, loss of consciousness and seizures. They usually appear in the prodromal phase. </p>
      <p id="paragraph-90dba276014e43df82a1915f2b3f13ce"><bold id="strong-af3a54e998314699aa8f60beac188b11">Auditory symptoms:</bold> Tinnitus, hipoacusia and vertigo. They can be present in all phases. </p>
      <p id="paragraph-2cb568b32cac4377a531d784fb39f7cb"><bold id="strong-ea3e37ab35bc4d94bed6cacaedc5ec69">Dermatological manifestations</bold>: Vitiligo, alopecia and poliosis; generally in the convalescence phase. </p>
      <p id="paragraph-a2839ce41c3b4d42b321e1126ee27192">The diagnosis is made through clinical criteria established and published by the American Uveitis Society in 2001. <xref id="xref-7d5dfbef8c6e41dcbb6ba700be2ddf60" rid="R104280321731168" ref-type="bibr">2</xref> The treatment is mainly based on systemic corticosteroids during the acute phase. Other treatment options include immunosuppressants such as azathioprine, cyclosporine, methotrexate and the use of immunoglobulins, <xref rid="R104280321731166" ref-type="bibr">3</xref>, <xref rid="R104280321731167" ref-type="bibr">4</xref> and the use of monoclonal antibodies such as adalimumab has been documented, which is associated with a lower risk of recurrence and visual impairment. <xref id="xref-29438dbaa7054d5e9cf650d79162241f" rid="R104280321731172" ref-type="bibr">5</xref> The complications that occur are related to the duration of the disease, recurrences and the age of the patient at the time of suffering from the disease. The complications that usually occur are cataracts, glaucoma, choroidal neovascularization and subretinal fibrosis. <xref id="xref-74125ecc6d6f4e358ba60ce7c9de2155" rid="R104280321731164" ref-type="bibr">6</xref></p>
    </sec>
    <sec>
      <title id="t-ae041ca9377c">Case report </title>
      <p id="paragraph-bdb508c52a874fa39ef8a4bb1f7bbdd3">A 45-years-old male, farmer presented with c/o diminished vision in BE for 1week associated with redness, pain, watering, intolerance to light and tinnitus which increases during night hours. Also, gives a history of similar complaints in the past 2years. Examination revealed both eye visual acuity CF1/2 meters. Slit lamp examination showed conjunctival ingestion, mutton fat KP’s on the posterior cornea, sluggishly reactive pupil with multiple broken posterior synechaie. Fundus showed hazy media with grade 2 vitreous cells, multiple vitreous opacities, diffuse retinochoroidal thickening, and multiple shallow serous retinal detachment with disc edema. Tonometry was 16 and 28 mmhg respectively. </p>
      <fig id="f-b07eaaa5e57f" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 1 </label>
        <caption id="c-132e79da5f2b">
          <title id="t-ff066f3e57f9">Anterior segment showing conjunctival ingestion</title>
        </caption>
        <graphic id="g-05b022e22299" xlink:href="https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ccd9aa5c-2269-4313-9cfd-83ec314ce817/image/42caf16f-62b1-461b-9dba-64af1ea134ab-uimage.png"/>
      </fig>
      <p id="p-cacb4bd26852"/>
      <fig id="f-4e6e076d316e" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 2 </label>
        <caption id="c-0a67cfdde2cd">
          <title id="t-9ccf9b38e488">Slit lamp picture showing broken posterior synechiae </title>
        </caption>
        <graphic id="g-951a1b9cfc56" xlink:href="https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ccd9aa5c-2269-4313-9cfd-83ec314ce817/image/0819d8f8-b246-43e8-981b-e1e295e2fbc4-uimage.png"/>
      </fig>
      <p id="p-0120a4f24150"/>
      <fig id="f-c32e0199faf3" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 3 </label>
        <caption id="c-10cc1088c301">
          <title id="t-c0e662e3e353">Slit lamp picture showing multiple mutton fat KP’S</title>
        </caption>
        <graphic id="g-3751a0ba808e" xlink:href="https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ccd9aa5c-2269-4313-9cfd-83ec314ce817/image/853ce7fb-7923-4476-b800-cc9d021a5d8d-uimage.png"/>
      </fig>
      <p id="p-03506c60ee24"/>
      <fig id="f-8e366303e8fb" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 4 </label>
        <caption id="c-884067e3e07e">
          <title id="t-a8850e138f26">Fundus picture showing diffuse retinochoroidal thickening</title>
        </caption>
        <graphic id="g-5ae5ef828130" xlink:href="https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ccd9aa5c-2269-4313-9cfd-83ec314ce817/image/b8d41c6d-b1a5-4863-b8dd-0a348b38a235-uimage.png"/>
      </fig>
      <p id="p-7ad8a7c11887"/>
      <p id="paragraph-8d7678f8f8c94e7698580c3fba339207"/>
      <fig id="f-22a0f10d240b" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 5 </label>
        <caption id="c-69ffa79fc388">
          <title id="t-bfca7e9b8ce8">Fundus picture showing disc edema</title>
        </caption>
        <graphic id="g-6f186df74f3e" xlink:href="https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ccd9aa5c-2269-4313-9cfd-83ec314ce817/image/321486d7-cb49-490f-adad-a3206677a1c9-uimage.png"/>
      </fig>
      <p id="paragraph-205b99da52384d4c8ee6c4dd7c9be15a">B-scan showed multiple vitreous echo’s, diffuse retinochoroidal complex thickening with multiple shallow serous retinal detachment, with optic disc edema. </p>
      <p id="paragraph-060ccad02c0f44b0a8ba738b0f0197e4">Lumbar puncture showed 82% lymphocytic pleocytosis.</p>
      <p id="paragraph-9f181c96d9c246ae97c9fe8f70e982b6">After routine investigations patient was started on topical and systemic steroids, cyclopegics and antiglaucoma drugs. IV methyl prednisolone 1mg/kg for 3days followed by oral steroids in a tapering dose. The patient recovered well with 6/24 vision in both eyes with resolution of fundus and b-scan findings at 6week followup.</p>
      <fig id="f-cf9f197d0d5a" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 6 </label>
        <caption id="c-f349c2b1351a">
          <title id="t-243c99692cf3">CSF pleocystosis</title>
        </caption>
        <graphic id="g-bf2215aaa244" xlink:href="https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ccd9aa5c-2269-4313-9cfd-83ec314ce817/image/f9a7f199-f564-4d79-bf4e-e0bb04398497-uimage.png"/>
      </fig>
      <p id="paragraph-db398ff443e448fbaef0417fc8e7ded7"/>
      <fig id="f-1ee9548227f6" orientation="portrait" fig-type="graphic" position="anchor">
        <label>Figure 7 </label>
        <caption id="c-a37f2869563d">
          <title id="t-334ba98c46bb">Diffuse RCC thickening with multiple serous RD</title>
        </caption>
        <graphic id="g-b7c58967de8b" xlink:href="https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/ccd9aa5c-2269-4313-9cfd-83ec314ce817/image/ca518c4b-49cf-4250-acfb-672f028e3e3c-uimage.png"/>
      </fig>
    </sec>
    <sec>
      <title id="title-f71f3d74acf147e39d19005fd007d207">Discussion</title>
      <p id="paragraph-e9cdcb1cfa544636a7c28d55ad0f2d6e">The reported clinical case meets the criteria to classify it as incomplete VKH disease, as it has ophthalmological implications that do not have a history of trauma or ocular surgery prior to the onset of symptoms, absence of evidence suggestive of another ocular disease, bilateral ocular involvement, and auditory manifestations, supporting the diagnosis in the presented imaging studies and intense pleocytosis in the cerebro-spinal fluid. It is not possible to detect dermatological manifestations since these are usually characteristic of the convalescence phase and are almost always detected at follow-up appointments. <xref rid="R104280321731169" ref-type="bibr">7</xref>, <xref rid="R104280321731165" ref-type="bibr">8</xref></p>
      <p id="paragraph-d2d8e1198b674422a264caae73c92e1c"> Inability to follow the patient deprives us of prognostic data of the particular case, as well as the detection of late-onset sequelae and their subsequent study.</p>
    </sec>
    <sec>
      <title id="title-ac11bf532e754496896ad8459e7088c1">Conclusion</title>
      <p id="paragraph-ccb43ba6d131437fb9061c63471f991a">High index of suspicion, timely diagnosis and management are crucial to prevent vision threatening complications in VKH disease. The rarity of this syndrome makes its diagnosis a challenge, the presence of tinitus and CNS findings must be considered. Long term followup is crucial for the detection of late onset sequelae and subsequent diagnosis of complete VKH disease.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R104280321731170">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Forster</surname>
              <given-names>D J</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>R L</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>N A</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Manifestations of VKH-Syndrome</article-title>
          <source>AMJ OPHTHALMOL</source>
          <year>1991</year>
          <volume>111</volume>
          <fpage>380</fpage>
          <lpage>322</lpage>
        </element-citation>
      </ref>
      <ref id="R104280321731168">
        <element-citation publication-type="misc">
          <person-group person-group-type="author">
            <name>
              <surname>Read</surname>
              <given-names>R W</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>VKH Disease. American Uveitis Society</article-title>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="R104280321731166">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lavezzo</surname>
              <given-names>M M</given-names>
            </name>
            <name>
              <surname>Sakata</surname>
              <given-names>V M</given-names>
            </name>
            <name>
              <surname>Morita</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>E E</given-names>
            </name>
            <name>
              <surname>Abdallah</surname>
              <given-names>S F</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>Felipe T G da</given-names>
            </name>
            <collab/>
            <etal/>
          </person-group>
          <source>Orphanet Journal of Rare Diseases</source>
          <year>2016</year>
          <volume>11</volume>
          <issue>29</issue>
          <fpage>1</fpage>
          <lpage>21</lpage>
          <object-id pub-id-type="doi">10.1186/s13023-016-0412-4</object-id>
        </element-citation>
      </ref>
      <ref id="R104280321731167">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Frutos</surname>
              <given-names>Anne Riveros</given-names>
            </name>
            <name>
              <surname>Romero</surname>
              <given-names>Pau Romera</given-names>
            </name>
            <name>
              <surname>Pérez</surname>
              <given-names>Susana Holgado</given-names>
            </name>
            <name>
              <surname>Escalona</surname>
              <given-names>José Ramón Anglada</given-names>
            </name>
            <name>
              <surname>Martínez-Morillo</surname>
              <given-names>Melania</given-names>
            </name>
            <name>
              <surname>Segura</surname>
              <given-names>Beatriz Tejera</given-names>
            </name>
            <collab/>
          </person-group>
          <person-group person-group-type="editor"/>
          <article-title>Enfermedad de Vogt-Koyanagi-Harada</article-title>
          <source>Seminarios de la Fundación Española de Reumatología</source>
          <volume>13</volume>
          <publisher-name>Elsevier BV</publisher-name>
          <year>2012</year>
          <fpage>142</fpage>
          <lpage>146</lpage>
          <object-id pub-id-type="doi">10.1016/j.semreu.2012.07.004</object-id>
        </element-citation>
      </ref>
      <ref id="R104280321731172">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Read</surname>
              <given-names>R W</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>G N</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>N A</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature</article-title>
          <source>Am J Ophthalmol</source>
          <year>2001</year>
          <volume>131</volume>
          <fpage>647</fpage>
          <lpage>52</lpage>
        </element-citation>
      </ref>
      <ref id="R104280321731164">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esparza</surname>
              <given-names>A M R</given-names>
            </name>
            <name>
              <surname/>
              <given-names>O A V Gurrola</given-names>
            </name>
            <name>
              <surname/>
              <given-names>O U S Alba</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Vogt-Koyanagi-Harada Incomplete Disease: A Case Report</article-title>
          <source>Intern Med</source>
          <year>2018</year>
          <volume>8</volume>
          <issue>5</issue>
          <fpage>1000291</fpage>
          <object-id pub-id-type="doi">10.4172/2165-8048.1000291</object-id>
        </element-citation>
      </ref>
      <ref id="R104280321731169">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname/>
              <given-names>G A O'Keefe</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>N A</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Vogt-Koyanagi-Harada disease</article-title>
          <source>Surv Ophthalmol</source>
          <year>2017</year>
          <volume>62</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>25</lpage>
          <object-id pub-id-type="doi">10.1016/j.survophthal.2016.05.002</object-id>
        </element-citation>
      </ref>
      <ref id="R104280321731165">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Douglas</surname>
              <given-names>A</given-names>
            </name>
            <collab/>
          </person-group>
          <article-title>Improving the diagnostic criteria for vogt-koyanagiharada disease</article-title>
          <source>JAMA ophthalmology</source>
          <year>2018</year>
          <volume>136</volume>
          <issue>9</issue>
          <fpage>1032</fpage>
          <lpage>1033</lpage>
          <object-id pub-id-type="doi">10.1001/jamaophthalmol.2018.2657</object-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
